Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine

por Zhang, Lei-Si, Wang, Jun, Xu, Ming-Zhu, Wu, Tian-Mei, Huang, Si-Man, Cao, Han-Yu, Sun, Ai-Ning, Liu, Song-Bai, Xue, Sheng-Li
Publicado 2022

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports

por Wang, Bin-Ru, Wan, Chao-Ling, Liu, Song-Bai, Qiu, Qiao-Cheng, Wu, Tian-Mei, Wang, Jun, Li, Yan-Yan, Ge, Shuai-Shuai, Qiu, Yan, Shen, Xiang-Dong, Xue, Sheng-Li, Li, Zheng
Publicado 2021

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report

por Huang, Si‐Man, Tao, Tao, Wan, Chao‐Ling, Wu, Tian‐Mei, Cao, Han‐Yu, Qiu, Yan, Shen, Xiang‐Dong, Wang, Bin‐Ru, Ge, Shuai‐Shuai, Li, Yan‐Yan, Zhang, Tong‐Tong, Wu, Bing, Xue, Sheng‐Li
Publicado 2023